AFM-30a

• Description :

  AFM-30a is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis[1].

• UNSPSC :

  12352005

• Target :

  Protein Arginine Deiminase

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/afm-30a.html

• Purity :

  96.0

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C2C(NCC2=CC=C1)=O)N[C@H](C3=NC4=C(N3C)C=CC=C4OC)CCCNC(CF)=N

• Molecular Formula :

  C24H27FN6O3

• Molecular Weight :

  466.51

• References & Citations :

  [1]Aaron Muth, et al. Development of a Selective Inhibitor of Protein Arginine Deiminase 2. J Med Chem. 2017 Apr 13;60 (7) :3198-3211.|[2]R. Surolia, et al. Role of PAD2 Regulated Inflammasome Signaling in Arsenic Induced Airway Inflammation and Remodeling. American Journal of Respiratory and Critical Care Medicine 2020;201:A2976.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2095107-57-4]